Journal Mobile Options
Table of Contents
Vol. 28, No. 3, 2011
Issue release date: 2011
Add to my selection Citation Download
Free Access
Cell Physiol Biochem 2011;28:545–552
(DOI:10.1159/000335119)
Review

SLC26A4 Genotypes and Phenotypes Associated with Enlargement of the Vestibular Aqueduct

Ito T.1 · Choi B.Y.2 · King K.A.1 · Zalewski C.K.1 · Muskett J.1 · Chattaraj P.1 · Shawker T.3 · Reynolds J.C.4 · Butman J.A.3 · Brewer C.C.1 · Wangemann P.5 · Alper S.L.6 · Griffith A.J.1
1Otolaryngology Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Rockville,2Laboratory of Molecular Genetics, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Rockville,3Diagnostic Radiology Department, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda,4Nuclear Medicine Department, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda,5Anatomy and Physiology Department, Kansas State University, Manhattan,6Beth Israel Deaconess Medical Center, Harvard Medical School, Boston Cell Physiol Biochem 2011;28:545–552 (DOI:10.1159/000335119)

Abstract

Enlargement of the vestibular aqueduct (EVA) is the most common inner ear anomaly detected in ears of children with sensorineural hearing loss. Pendred syndrome (PS) is an autosomal recessive disorder characterized by bilateral sensorineural hearing loss with EVA and an iodine organification defect that can lead to thyroid goiter. Pendred syndrome is caused by mutations of the SLC26A4 gene. SLC26A4 mutations may also be identified in some patients with nonsyndromic EVA (NSEVA). The presence of two mutant alleles of SLC26A4 is correlated with bilateral EVA and Pendred syndrome, whereas unilateral EVA and NSEVA are correlated with one (M1) or zero (M0) mutant alleles of SLC26A4. Thyroid gland enlargement (goiter) appears to be primarily dependent on the presence of two mutant alleles of SLC26A4 in pediatric patients, but not in older patients. In M1 families, EVA may be associated with a second, undetected SLC26A4 mutation or epigenetic modifications. In M0 families, there is probably etiologic heterogeneity that includes causes other than, or in addition to, monogenic inheritance.

 goto top of outline Author Contacts

Andrew J. Griffith, MD, PhD
Otolaryngology Branch
National Institute on Deafness and Other Communication Disorders
5 Research Court, Rockville, Maryland 20850-3320 (USA)
Tel. +1-301-402-2829, Fax +1-301-402-7580, E-Mail griffita@nidcd.nih.gov


 goto top of outline Article Information

Accepted: October 11, 2011
Published online: November 18, 2011
Number of Print Pages : 8


 goto top of outline Publication Details

Cellular Physiology and Biochemistry (International Journal of Experimental Cellular Physiology, Biochemistry andPharmacology)

Vol. 28, No. 3, Year 2011 (Cover Date: 2011)

Journal Editor: F. Lang, Tübingen
ISSN: 1015–8987 (Print), eISSN: 1421–9778 (Online)

For additional information: http://www.karger.com/journals/cpb


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.